VXRT News and Press, Vaxart Inc. From 05/13/24

2024-05-13 17:49:08 ET Vaxart, Inc. (VXRT) Q1 2024 Earnings Conference Call May 13, 2024 4:30 p.m. ET Company Participants Ed Berg - Senior Vice President and General Counsel Steven Lo - Chief Executive Officer Sean Tucker - Founder and Chief Scientific Officer ...

2024-05-13 17:01:34 ET More on Vaxart Vaxart, Inc. (VXRT) Q4 2023 Earnings Call Transcript Vaxart GAAP EPS of -$0.14 in-line, revenue of $2.18M beats by $1.38M Vaxart FY 2023 Earnings Preview Seeking Alpha’s Quant Rating on Vaxart Historical ea...

2024-05-13 16:03:48 ET More on Vaxart Vaxart, Inc. (VXRT) Q4 2023 Earnings Call Transcript Vaxart FY 2023 Earnings Preview Vaxart appoints Steven Lo as president, CEO, and director Seeking Alpha’s Quant Rating on Vaxart Historical earnings data...

Positive results from Phase 1 norovirus study in lactating mothers indicate the potential of Vaxart’s oral pill vaccine candidate to protect or reduce the effect of the disease in infants Expects to initiate Phase 2b study evaluating Vaxart’s oral pill XBB COVID-19 vaccine a...

2024-05-13 13:07:36 ET More on GameStop: GameStop: Approaching An Optimistic Fair Value But Not There Yet GameStop: Operations Are Stabilizing, But Expect More Pain To Come GameStop: Compelling Risk To Reward Profile Ahead Of Q4 Earnings GameStop's sudden mem...

Aileron Therapeutics Inc. (ALRN) is expected to report for Q1 2024 DZS Inc. (DZSI) is expected to report $-0.09 for Q1 2024 Bitfarms Ltd. (BITF) is expected to report $-0.03 for Q1 2024 180 Degree Capital Corp. (TURN) is expected to report for quarter end 2024-03-31 Abacus Life In...

Conference call to begin at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced it will provide a business update and report financial results for the first quarter ended March 31, 2024 after the market close on Monda...

Antibody rise observed in lactating mothers and in their breast milk Long-term goal is to provide protection to infants through passive antibody transfer SOUTH SAN FRANCISCO, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that it has complet...

SOUTH SAN FRANCISCO, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker, Founder and Chief Scientific Officer, will present at the World Vaccine Congress Washington 2024 in Washington, D.C. on Wednesday, April 3, 2024. The Company has appea...

SOUTH SAN FRANCISCO, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (the “Company” or “Vaxart”) today announced that the Compensation Committee of the Board of Directors approved certain equity awards to the Company’s new President and Ch...